Variant · Expression
ERBB3 Overexpression
CI-VAR-00003130Explore in graph →CIViC 289
Curated evidence
Evidence by cancer (8 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26920887
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HER2-Positive Breast Carcinoma1 | ||||||||
| ERBB3 Overexpression | Trastuzumab Emtansine | Predictive | B | Does Not Support Resistance | 2 | accepted | EID8707In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma1 | ||||||||
| ERBB3 Overexpression | Pertuzumab | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID7804Two lung cancer cell lines, 11_18 and Ma-24, were found to have significantly increased growth when treated with heregulin (HRG)‐α compared to other growth factors. Pertuzumab was found to significan… (full text at CIViC) | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available